Home โบ Meningioma
Meningioma clinical trials recruiting in the U.S.
28 studies for Meningioma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY8 studies
- Miami, FL7 studies
- Boston, MA6 studies
- Columbus, OH6 studies
- San Francisco, CA5 studies
- San Diego, CA5 studies
- Atlanta, GA5 studies
- Jacksonville, FL5 studies
- Phoenix, AZ4 studies
- Arlington, VA4 studies
- Houston, TX4 studies
- Detroit, MI4 studies
- Durham, NC3 studies
- St. Louis, MO3 studies
- Los Angeles, CA3 studies
- Cincinnati, OH3 studies
- Baltimore, MD3 studies
- Seattle, WA3 studies
- Cedar Rapids, IA3 studies
- Tampa, FL3 studies
- Milwaukee, WI3 studies
- Omaha, NE3 studies
- Nashville, TN3 studies
By state
- Arizona4 studies
- California12 studies
- Florida7 studies
- Georgia5 studies
- Indiana3 studies
- Iowa3 studies
- Kentucky3 studies
- Maryland5 studies
- Massachusetts6 studies
- Michigan4 studies
- Minnesota4 studies
- Missouri3 studies
- Nebraska3 studies
- New Hampshire3 studies
- New York9 studies
- North Carolina5 studies
- Ohio7 studies
- Pennsylvania3 studies
- Tennessee4 studies
- Texas4 studies
- Virginia4 studies
- Washington3 studies
- Wisconsin4 studies
Recently updated studies
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT02523014Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT06955169Natural History Study of Patients With Neurofibromatosis Type 2
RecruitingObservational study
Ages 8 to 75 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT00598351UCSD Image-Guided Cognitive-Sparing Radiosurgery for Intracranial Lesions
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 8, 2026 ยท NCT04343157A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 8, 2026 ยท NCT07428616Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Sep 2, 2026 ยท NCT04374305Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
Recruiting
Ages 18 and older ยท All sexes ยท Updated Aug 26, 2026 ยท NCT06557512Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Aug 14, 2026 ยท NCT06014905RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Aug 13, 2026 ยท NCT07150806A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Jul 30, 2026 ยท NCT07533942Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
RecruitingObservational study
All ages ยท All sexes ยท Updated Jul 22, 2026 ยท NCT04427384Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 ยท All sexes ยท Updated Jul 20, 2026 ยท NCT05278208Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Jun 30, 2026 ยท NCT07493447Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RecruitingObservational study
Ages 18 to 99 ยท All sexes ยท Updated Jun 10, 2026 ยท NCT05576103Cognitive Status After Removal of Skull Base Meningioma
RecruitingObservational study
Ages 18 to 89 ยท All sexes ยท Updated May 22, 2026 ยท NCT04635657Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated May 19, 2026 ยท NCT07418775Cabozantinib for Patients With Recurrent or Progressive Meningioma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated May 14, 2026 ยท NCT05425004Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
RecruitingPhase 1/2
Ages 18 to 90 ยท All sexes ยท Updated May 14, 2026 ยท NCT05636618Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Apr 22, 2026 ยท NCT04082520Abemaciclib in Newly Diagnosed Meningioma Patients
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Mar 13, 2026 ยท NCT05940493Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
RecruitingPhase 4
Ages 18 to 99 ยท All sexes ยท Updated Feb 27, 2026 ยท NCT06377371Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
Recruiting
Ages 18 and older ยท All sexes ยท Updated Feb 17, 2026 ยท NCT04278118Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Feb 10, 2026 ยท NCT06132685Evaluation of the CONVIVO System
Recruiting
Ages 18 and older ยท All sexes ยท Updated Feb 6, 2026 ยท NCT05139277Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Feb 5, 2026 ยท NCT06650163From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.